Summaries for patients. Long-term outcomes of treating nonacute Chagas disease with benznidazole.
D000328:Adult; D000818:Animals; D000913:Antibodies, Protozoan / Q000097:blood; D002598:Chagas Cardiomyopathy / Q000175:diagnosis* / Q000209:etiology; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology / Q000503:physiopathology; D002908:Chronic Disease; D018450:Disease Progression; D004562:Electrocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009593:Nitroimidazoles / Q000627:therapeutic use*; D011379:Prognosis; D012680:Sensitivity and Specificity; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000276:immunology
D000913:Antibodies, Protozoan; D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole